You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

CLINICAL TRIALS PROFILE FOR MERCAPTOPURINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for mercaptopurine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Medical Research Council Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed National Cancer Institute (NCI) Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Eastern Cooperative Oncology Group Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002531 ↗ Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia Unknown status Johann Wolfgang Goethe University Hospital Phase 2 1993-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of various combination chemotherapy regimens in treating patients with acute lymphocytic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mercaptopurine

Condition Name

Condition Name for mercaptopurine
Intervention Trials
Leukemia 62
Acute Lymphoblastic Leukemia 48
Ulcerative Colitis 16
Crohn's Disease 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mercaptopurine
Intervention Trials
Leukemia 160
Precursor Cell Lymphoblastic Leukemia-Lymphoma 152
Leukemia, Lymphoid 146
Lymphoma 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mercaptopurine

Trials by Country

Trials by Country for mercaptopurine
Location Trials
Canada 241
Australia 91
Spain 44
France 37
Germany 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mercaptopurine
Location Trials
Texas 75
California 68
New York 61
Tennessee 59
Illinois 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mercaptopurine

Clinical Trial Phase

Clinical Trial Phase for mercaptopurine
Clinical Trial Phase Trials
Phase 4 32
Phase 3 86
Phase 2/Phase 3 8
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mercaptopurine
Clinical Trial Phase Trials
Completed 120
Recruiting 38
Unknown status 23
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mercaptopurine

Sponsor Name

Sponsor Name for mercaptopurine
Sponsor Trials
National Cancer Institute (NCI) 74
Children's Oncology Group 30
M.D. Anderson Cancer Center 15
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mercaptopurine
Sponsor Trials
Other 332
NIH 81
Industry 67
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Mercaptopurine Market Analysis and Financial Projection

Mercaptopurine: Clinical Trials, Market Analysis, and Projections

Introduction

Mercaptopurine, a nucleoside metabolic inhibitor, is widely used in the treatment of various conditions, including ulcerative colitis (UC) and certain types of leukemia. This article provides an update on the recent clinical trials, market analysis, and projections for mercaptopurine.

Clinical Trials Update

Recent Studies on Ulcerative Colitis

A significant recent study on mercaptopurine for the treatment of ulcerative colitis was a prospective, randomized, double-blind, placebo-controlled trial. This trial, conducted between December 2016 and April 2021, involved 59 patients randomized to either mercaptopurine or placebo for 52 weeks. Patients continued to receive 5-aminosalicylates (5-ASA) and corticosteroids for the first 8 weeks. The primary endpoint was corticosteroid-free clinical remission and endoscopic improvement at week 52.

  • Outcomes: The study found that 55.2% of patients in the mercaptopurine group completed the 52-week study, compared to 43.3% in the placebo group. The primary endpoint was achieved by 48.3% of patients on mercaptopurine versus 10% on placebo, with a significant difference of 38.3% (95% CI 17.1-59.4, p = 0.002)[1][4].

Adverse Events and Dose Adjustments

The study highlighted that adverse events occurred more frequently in the mercaptopurine group, with 808.8 events per 100 patient-years compared to 501.4 events per 100 patient-years in the placebo group. Therapeutic drug monitoring (TDM) was crucial, with dose adjustments made in 75.9% of patients, leading to lower mercaptopurine doses at week 52 compared to baseline[1][4].

Ongoing and Future Trials

Several ongoing clinical trials are exploring the efficacy and safety of mercaptopurine in various settings. For example, trials sponsored by Lucile Packard Children's Hospital Foundation, Stanford University, and Amgen are in Phase 1/Phase 2, focusing on different aspects of mercaptopurine treatment[3].

Market Analysis

Global Market Size and Growth

The global mercaptopurine drugs market is projected to grow significantly. As of 2023, the market was estimated to be worth approximately $418 million. It is forecasted to reach $627.3 million by 2030, with a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period of 2024-2030[2][5].

Market Segmentation

The market is segmented by type, application, and region. Key segments include:

  • Type: Mercaptopurine is available in different concentrations, such as 20mg/ml and 5mg/ml.
  • Application: The drug is used in hospitals and pharmacies.
  • Region: The market is analyzed across North America, Europe, Asia Pacific, South America, and the Middle East and Africa[2][5].

Competitive Landscape

The competitive landscape of the mercaptopurine market includes major manufacturers such as Nova Laboratories. The report provides insights into the sales, revenue, market share, and industry ranking of these manufacturers, helping stakeholders understand the competitive dynamics and position their businesses strategically[2][5].

Market Projections

Regional Growth

The market growth is expected to be robust across various regions. North America, Europe, and the Asia Pacific are anticipated to be key drivers of this growth. The report provides detailed country-specific data and market value analysis for regions such as the U.S., Canada, Mexico, Brazil, China, Japan, and others[2][5].

Forecasted Sales and Revenue

The forecasted sales and revenue for mercaptopurine drugs are expected to increase steadily. The report includes revenue and volume forecasts, company share analysis, and competitive landscape assessments to help stakeholders navigate the market effectively[2][5].

Pharmacology and Mechanism of Action

Drug Class and Mechanism

Mercaptopurine is classified as a nucleoside metabolic inhibitor. It acts by inhibiting nucleic acid synthesis, which is crucial for cell proliferation. This mechanism makes it effective in treating conditions characterized by rapid cell division, such as certain cancers and autoimmune diseases like ulcerative colitis[3].

Key Takeaways

  • Clinical Efficacy: Mercaptopurine has shown significant efficacy in achieving clinical, endoscopic, and histological improvements in patients with ulcerative colitis.
  • Market Growth: The global mercaptopurine market is projected to grow from $418 million in 2023 to $627.3 million by 2030, with a CAGR of 6.3%.
  • Adverse Events: While mercaptopurine is effective, it is associated with a higher frequency of adverse events, emphasizing the need for therapeutic drug monitoring.
  • Regional Dynamics: The market is expected to grow across various regions, with North America, Europe, and the Asia Pacific being key contributors.

FAQs

What is the primary use of mercaptopurine in clinical settings?

Mercaptopurine is primarily used in the treatment of ulcerative colitis and certain types of leukemia.

What were the key findings of the recent clinical trial on mercaptopurine for ulcerative colitis?

The trial found that mercaptopurine was superior to placebo in achieving corticosteroid-free clinical remission and endoscopic improvement at 52 weeks, with 48.3% of patients on mercaptopurine achieving the primary endpoint compared to 10% on placebo[1][4].

What is the projected market size for mercaptopurine drugs by 2030?

The global mercaptopurine drugs market is forecasted to reach $627.3 million by 2030, growing at a CAGR of 6.3% from 2024 to 2030[2][5].

Which regions are expected to drive the growth of the mercaptopurine market?

North America, Europe, and the Asia Pacific are anticipated to be key drivers of the market growth[2][5].

What is the mechanism of action of mercaptopurine?

Mercaptopurine acts as a nucleoside metabolic inhibitor, inhibiting nucleic acid synthesis which is crucial for cell proliferation[3].

Sources

  1. Mercaptopurine for the Treatment of Ulcerative Colitis. European Crohn’s and Colitis Organisation, 2023.
  2. Global Mercaptopurine Drugs Market Insights, Forecast to 2030. QY Research, 2024.
  3. Generic MERCAPTOPURINE INN entry, drug patent and freedom to operate. Drug Patent Watch.
  4. Mercaptopurine for the Treatment of Ulcerative Colitis - PubMed. PubMed, 2023.
  5. Mercaptopurine Drugs - Market Size - Valuates Reports. Valuates Reports.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.